483
Baxter Healthcare (Guangzhou) Co., Ltd.FDA 483 - Baxter Healthcare (Guangzhou) Co., Ltd. - December 13, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Baxter Healthcare (Guangzhou) Co., Ltd. revealed critical deficiencies in quality control and aseptic manufacturing processes. The firm failed to reject defective components, lacked adequate controls to prevent microbiological contamination of sterile drug products, and exhibited poor data integrity practices. These issues led to the shipment of potentially compromised sterile drugs to the U.S. market.
Open in Dashboard
ID · c22ba2a6-ed5b-43f3-a2ec-eed7ca3d3e7e